PTSDMicrodosingImmunology & InflammationLSDMescalinePsilocybin

Three Cases of Reported Improvement in Microsmia and Anosmia Following Naturalistic Use of Psilocybin and LSD

This case report (n=3) documents the first academic instances of olfactory improvement after psychedelic use. The study also discusses potential mechanisms, such as serotonergic effects, neuroplasticity, and anti-inflammatory effects, suggesting further research into psychedelics for olfactory dysfunction.

Authors

  • Brian Barnett

Published

Journal of Psychoactive Drugs
individual Study

Abstract

Cultural awareness of anosmia and microsmia has recently increased due to their association with COVID-19, though treatment for these conditions is limited. A growing body of online media claims that individuals have noticed improvement in anosmia and microsmia following classic psychedelic use. We report what we believe to be the first three cases recorded in the academic literature of improvement in olfactory impairment after psychedelic use. In the first case, a man who developed microsmia after a respiratory infection experienced improvement in smell after the use of 6 g of psilocybin containing mushrooms. In the second case, a woman with anosmia since childhood reported olfactory improvement after ingestion of 100 µg of lysergic acid diethylamide (LSD). In the third case, a woman with COVID-19-related anosmia reported olfactory improvement after microdosing 0.1 g of psilocybin mushrooms three times. Following a discussion of these cases, we explore potential mechanisms for psychedelic-facilitated improvement in olfactory impairment, including serotonergic effects, increased neuroplasticity, and anti-inflammatory effects. Given the need for novel treatments for olfactory dysfunction, increasing reports describing improvement in these conditions following psychedelic use and potential biological plausibility, we believe that the possible therapeutic benefits of psychedelics for these conditions deserve further investigation.

Available with Blossom Pro

Research Summary of 'Three Cases of Reported Improvement in Microsmia and Anosmia Following Naturalistic Use of Psilocybin and LSD'

Introduction

Olfactory dysfunction (OD), including anosmia (loss of smell) and microsmia (reduced smell), is associated with reduced quality of life across mood, safety, social engagement, and appetite. Common causes include sinonasal disease, trauma, and post-infectious injury; recent attention has focused on post-infectious OD because of the frequency and persistence of smell loss following COVID-19 infection. Existing treatments for post-infectious OD are limited: olfactory training has some supporting randomised evidence but modest benefit, while pharmacological and procedural options (topical/oral steroids, antibiotics, alpha-lipoic acid, stellate ganglion block, surgery) lack consistent efficacy for sensorineural forms of OD. Kovacevich and colleagues report what they describe as the first three cases in the medical literature of subjective or objective improvement in anosmia/microsmia following naturalistic use of classic psychedelics (psilocybin and LSD). The authors note that social and traditional media have suggested similar improvements and argue biological plausibility via serotonergic effects, enhanced neuroplasticity, and anti-inflammatory actions of classic psychedelics. The paper aims to present these three cases, document available objective testing where present, and explore potential mechanisms to motivate further formal investigation.

Expert Research Summaries

Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.

Study Details

References (20)

Papers cited by this study that are also in Blossom

Case report: Prolonged amelioration of mild red-green color vision deficiency following psilocybin mushroom use

Barnett, B. S., Sweat, N. W., Hendricks, P. S. · Drug Science Policy and Law (2023)

4 cited
Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin

Barrett, F. S., Johnson, M. W., Griffiths, R. R. · Journal of Psychopharmacology (2015)

Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study

Bogenschutz, M. P., Forcehimes, A. A., Pommy, J. A. et al. · Journal of Psychopharmacology (2015)

Towards an understanding of psychedelic-induced neuroplasticity

Calder, A. E., Hasler, G. · Neuropsychopharmacology (2022)

Psychedelics as anti-inflammatory agents

Flanagan, T. W., Nichols, C. D. · International Review of Psychiatry (2018)

Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction

Garcia-Romeu, A., Griffiths, R. R., Johnson, M. W. · Current Drug Abuse Reviews (2015)

Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up

Davis, A. K., Streeter Barrett, F., Cosimano, M. P. et al. · Journal of Psychopharmacology (2022)

306 cited
Show all 20 references
Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanisms

Inserra, A., De Gregorio, D., Gobbi, G. · Pharmacological Reviews (2021)

Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function

Johnson, M. W., Hendricks, P. S., Barrett, F. S. et al. · Pharmacology and Therapeutics (2019)

Hallucinogens and Serotonin 5-HT2A Receptor-Mediated Signaling Pathways

López-Giménez, J. F., González-Maeso, J. · Current Topics in Behavioral Neurosciences (2017)

211 cited
Psychedelics promote structural and functional neural plasticity

Ly, C., Greb, A. C., Cameron, L. P. et al. · Cell Reports (2018)

Psychedelics promote plasticity by directly binding to BDNF receptor TrkB

Moliner, R., Girych, M., Brunello, C. A. et al. · Nature Neuroscience (2023)

The fabric of meaning and subjective effects in LSD-induced states depend on serotonin 2A receptor activation

Preller, K. H., Herdener, M., Pokorny, T. et al. · Current Biology (2017)

Quality of acute psychedelic experience predicts therapeutic efficacy of psilocybin for treatment-resistant depression

Roseman, L., Nutt, D. J., Carhart-Harris, R. L. · Frontiers in Pharmacology (2018)

Adverse effects of psychedelics: From anecdotes and misinformation to systematic science

Neil, J. C., Nutt, D. J. · Journal of Psychopharmacology (2022)

Psychedelics promote neuroplasticity through the activation of intracellular 5-HT2A receptors

Vargas, M. V., Dunlap, L. E., Dong, C. et al. · Science (2023)

330 cited

Your Personal Research Library

Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.